



[www.proteologics.com](http://www.proteologics.com)

Contact Person:  
**Mr. Avishai Levy**  
avishai@proteologics.com

**Proteologics** is an integrated biotechnology SME, aspires to become a fully integrated pharmaceutical company and a leader in the emerging field of the ubiquitin-related drugs. Proteologics identifies new correlations between ubiquitin pathway components and pathological conditions. Once specific E3 targets are discovered and validated, we proceed to establishing proprietary technologies for the accelerated hit-to-lead drug discovery process. Proteologics' recognized competencies are built through a number of internal programs and partnerships, including a strategic R&D collaboration with Teva Pharmaceutical Industries Ltd.



## Success Story of Proteologics Ltd.



[www.smesgolifesciences.org](http://www.smesgolifesciences.org)

### EU FP Project : RUBICON

**Project Title: Role of ubiquitin and ubiquitin-like modifiers in cellular regulation**

**Call details:**

Priority : LSH  
Submission date : 16.11.2004  
Reference : LSH-2004-1.1.5-1

**Project type:**

Integrated Project  
● Network of Excellence  
Specific Targeted Research Project

**Website:** [www.rubicon-net.org](http://www.rubicon-net.org)

**Project Abstract:** INRUBICON is a Network of Excellence, funded by the European Community, with the aim to establish a European forum for research on the molecular principles and regulatory roles of protein modifications by linkage of ubiquitin and ubiquitin-like molecules. RUBICON brings together investigators from different backgrounds that will work together in a multi-disciplinary effort to develop the knowledge base for the discovery of novel mechanism-based therapeutic approaches to disease.

### Consortium composition : 21 partners from 7 countries

Karolinska Institutet	SE	Universitat Stuttgart	DE
The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital	NL	Ifom Fondazione Istituto Firc Di Oncologia Molecolare	IT
University Medical Center	NL	<b>Proteologics Ltd</b>	<b>IL</b>
University of St Andrews	GB	Technion - Israel Institute of Technology	IL
Medical Research Council	GB	The Hebrew University of Jerusalem	IL
Institut Pasteur	FR	Centre National de la Recherche Scientifique	FR
Centre National de la Recherche Scientifique	FR	<b>Pepscan Systems</b>	<b>NL</b>
Max Planck Society for the Advancement of Science	DE	<b>Drug Discovery Factory BV</b>	<b>NL</b>
Bereich Humanmedizin der Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts	DE	<b>Cytomics Systems</b>	<b>FR</b>
Universitat Konstanz	DE	<b>Affiniti Research Products Ltd trading as BIOMOL International LP</b>	<b>GB</b>
Max-Delbruck-Center for Molecular Medicine	DE		

### Proteologics in RUBICON

**Proteologics'** role in the Project is to combine world-class knowledge of the ubiquitin system with a unique platform that helps to discover the involvement of ubiquitin ligases in diseases and develop inhibitors to them. Mr. Avishai Levy, CEO, Proteologics says, "Proteologics was asked to join the RUBICON project. Proteologics' interest in joining the project was access to knowledge as a partner in a NoE project. Yet, joining a project of 21 partners, raised

questions about the Intellectual Property Rights issues. The solution to this situation was a simple one – all partners had the right to specifically exclude IP."

**SMEs go LifeSciences partner (ISERD)** assisted Proteologics in various ways such as introduction us to FP6, explanations on how to look for partners, introduction to the data base of SGLS and advised us on IPR issues.

**SMEs go LifeSciences partner :**

**ISERD** - [www.iserd.org.il](http://www.iserd.org.il)  
**Contact Person :** Dr. Eva Rockman - [eva@iserd.org.il](mailto:eva@iserd.org.il)

